AL
ALGS.US Aligos Therapeutics Inc
- Market cap
- USD 13.1M
- P/E
- -
- P/B
- 1.09x
- ROE
- -547.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALGS.US undervalued?
Graham numberThe Graham number of Aligos Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aligos Therapeutics Inc fundamental analysis
No fundamental analysis for Aligos Therapeutics Inc yet.
Aligos Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial;…
Full company profileAligos Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aligos Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | -10.5M | 4.36M | 13.9M | 15.5M | 3.95M | 2.19M | 44.6M |
| Gross Profit | -1.29M | -2.30M | -10.5M | 4.36M | 13.9M | 15.5M | 3.95M | 1.26M | 44.6M |
| Operating Income | -13.7M | -54.0M | -97.8M | -128M | -97.6M | -88.1M | -89.2M | -88.0M | -67.6M |
| EBITDA | -12.4M | -49.9M | -94.5M | -125M | -93.9M | -83.8M | -128M | -22.9M | -56.5M |
| Net Income | -13.9M | -52.3M | -109M | -128M | -96.0M | -87.7M | -131M | -24.2M | -61.9M |
| EPS | -0.66 | -2.38 | -3.18 | -3.22 | -2.25 | -3.52 | -21 | -2.45 | -5.91 |
| Balance Sheet | |||||||||
| Total Assets | 108M | 147M | 265M | 235M | 147M | 152M | 70.1M | 88.5M | 47.2M |
| Total Liabilities | 121M | 211M | 45.3M | 50.6M | 42.8M | 59.4M | 99.1M | 35.0M | 35.9M |
| Shareholders' Equity | -13.7M | -64.9M | 220M | 185M | 104M | 92.1M | -29.0M | 53.5M | 11.3M |
| Cash & Short-term Investments | 90.9M | 118M | 244M | 191M | 126M | 136M | 56.9M | 77.8M | 31.1M |
| Total Debt | 13.9M | 14.3M | 13.0M | 14.5M | 12.6M | 11.1M | 8.38M | 5.25M | 11.9M |
| Cash Flow | |||||||||
| Operating Cash Flow | -6.05M | -46.8M | -74.3M | -116M | -79.4M | -79.0M | -80.7M | -82.5M | -62.2M |
| Capital Expenditure | 2.52M | 2.79M | 2.06M | 892K | 943K | 19.0K | 130K | 437K | 263K |
| Free Cash Flow | -8.57M | -49.6M | -76.3M | -117M | -80.3M | -79.0M | -80.9M | -82.9M | -62.4M |
| Ratios | |||||||||
| ROE | - | - | -49.3% | -69.5% | -92.4% | -95.2% | - | -45.2% | -547.2% |
| ROA | -12.9% | -35.7% | -40.9% | -54.5% | -65.5% | -57.9% | -187.2% | -27.3% | -131.1% |
| Net Profit Margin | - | - | - | -2,944.1% | -690.6% | -564.6% | -3,326.0% | -1,106.7% | -138.6% |
| Debt to Equity | - | - | 0.06x | 0.08x | 0.12x | 0.12x | - | 0.10x | 1.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aligos Therapeutics Inc dividends
Aligos Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:25 on Aug 19, 2024.
Who owns Aligos Therapeutics Inc
- Insiders 10.64%
- Institutions 42.89%
- Public & others 46.47%
- Shares outstanding 5.45M
- Free float 3.68M
Top funds holding ALGS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 129K | 2.06% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 26.7K | 0.43% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 14.9K | 0.24% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 8.33K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 7.55K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 6.14K | 0.10% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 3.57K | 0.06% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 2.81K | 0.05% | 0.00% | Oct 2026 |
| DFA U.S. Vector Equity I | 2.09K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 1.86K | 0.03% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 1.43K | 0.02% | 0.00% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 1.20K | 0.02% | -25.00% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 1.15K | 0.02% | -0.26% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 1.15K | 0.02% | 0.00% | Oct 2026 |
| 1290 VT Micro Cap K | 1.09K | 0.02% | 0.00% | Sep 2026 |
| Avantis U.S. Small Cap Equity G | 332.00 | 0.01% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 224.00 | 0.00% | +25.84% | Aug 2026 |
| Global Core Equity UCITS ETF USD Acc | 83.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding ALGS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 444K | 7.11% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 412K | 6.60% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 327K | 5.24% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 247K | 3.95% | -7.70% | Jun 2026 |
| Woodline Partners LP | 177K | 2.84% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 176K | 2.81% | -1.53% | Jun 2026 |
| Baker Bros Advisors LP | 83.1K | 1.33% | 0.00% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 76.2K | 1.22% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 66.5K | 1.06% | +505.42% | Jun 2026 |
| UBS Group AG | 60.0K | 0.96% | +61.86% | Jun 2026 |
| Geode Capital Management, LLC | 47.2K | 0.76% | -5.61% | Jun 2026 |
| Jane Street Group LLC | 32.4K | 0.52% | 0.00% | Jun 2026 |
| BlackRock Inc | 30.3K | 0.49% | +132.30% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 28.6K | 0.46% | +0.62% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 21.0K | 0.34% | 0.00% | Sep 2026 |
| Verition Fund Managegment, LLC | 18.9K | 0.30% | 0.00% | Jun 2026 |
| Trexquant Investment LP | 12.3K | 0.20% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 10.8K | 0.17% | -89.25% | Jun 2026 |
| Rockefeller Capital Management L.P. | 10.0K | 0.16% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 4.65K | 0.07% | +389.47% | Jun 2026 |
Aligos Therapeutics Inc company profile
- Company name
- Aligos Therapeutics Inc
- Ticker
- ALGS.US
- Exchange
- USA Stocks
- Listed since
- Oct 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 82
- Fiscal year end
- December
- Address
- One Corporate Drive, South San Francisco, CA, United States, 94080
- Phone
- 800 466 6059
- Website
- aligos.com
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Aligos Therapeutics Inc management
10- Dr. Lawrence M. Blatt MBA, Ph.D.CEO, President & Chairman of the Board · born 1962
- Ms. Lesley Ann Calhoun CPAExecutive VP, CFO & COO · born 1966
- Dr. Julian A. Symons DPHILExecutive VP & Chief Scientific Officer · born 1962
- Mr. Nikhil AnejaPrincipal Accounting Officer · born 1977
- Ms. Laura KavanaughVP & Head of Legal
- Ms. Kristina Engeseth M.B.A.Senior VP and Head of People & Culture
- Dr. Sushmita M. Chanda DABT, Ph.D.Executive Vice President & Chief Development Officer · born 1967
- Dr. David B. Smith Ph.D.Executive VP & Head of Chemical Operations
- Dr. Tse-I Lin Ph.D.Senior VP of Early Compound Development & Belgian Site Head
- Dr. Kieron Wesson Ph.D.Vice President & Head of Chemistry Manufacturing Controls